Taming the beast

Even as the hedge fund industry gears up for an expected new push by US regulators to register with the Securities and Exchange Commission (SEC), new rules targeting over-the-counter derivatives markets could have just as significant an impact on how hedge funds and investment managers do business, and which technologies they'll need to do so.

No doubt buy-side firms would like to know exactly how a new regulatory regime for OTC derivatives would affect them operationally, but although more detai

To continue reading...

You must be signed in to use this feature.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: